Le Lézard
Classified in: Health, Covid-19 virus
Subject: LEG

ATA President, Dr. Joe Kvedar, Testifies at Senate Committee Hearing on Telehealth


WASHINGTON, June 17, 2020 /PRNewswire/ -- American Telemedicine Association (ATA) President, Joseph C. Kvedar, MD, testified today before the full Senate Committee on Health, Education, Labor and Pensions (HELP) on telehealth, urging policymakers to "take specific actions before the end of the public health emergency to make access to telehealth services  permanent."

In response to the COVID-19 pandemic, Congress and the federal government have removed many of the antiquated barriers to telehealth that have traditionally kept providers from reaching their patients remotely. As a result, telehealth has saved lives, helped reduce the spread of the virus, and enabled providers to scale the response of an overwhelmed health system during the pandemic. During today's hearing, senators asked witnesses how these regulatory flexibilities have improved access to care and what policies should remain permanent when the public health emergency ends.

To ensure patients?including Medicare beneficiaries?continue to be empowered with the option to use telehealth, Dr. Kvedar and the ATA are urging Congress to move quickly to enact targeted telehealth reform legislation before the public health emergency declaration is rescinded. 

"I have seen first-hand the many ways telehealth bridges the gap between a critical provider shortage and a growing patient population ? a problem that existed prior to the pandemic, and one that will only worsen," said Kvedar, Professor, Harvard Medical School, Senior Advisor, Virtual Care, Mass General Brigham (Partners HealthCare), and ATA President. "However, we need Congress's support to ensure patients and providers do not go over the telehealth 'cliff' as our nation eventually emerges from the pandemic. We must make sure that essential  telehealth services do not abruptly end with the public health emergency, especially as we look to reorient our healthcare system to deliver 21st century care."

Dr. Kvedar's full testimony is available here. A recording of today's full hearing can be found here.

Also testifying today was former ATA President Karen S. Rheuban, MD, Professor of Pediatrics, Senior Associate Dean of Continuing Medical Education, and Director, University of Virginia Karen S. Rheuban Center for Telehealth.

About the ATA
As the only organization completely focused on advancing telehealth, the ATA is committed to ensuring that everyone has access to safe, affordable, and appropriate care when and where they need it, enabling the system to do more good for more people. ATA represents a broad and inclusive member network of health care delivery systems, academic institutions, technology solution providers and payers, as well as partner organizations and alliances, working to advance industry adoption of telehealth, promote responsible policy, advocate for government and market normalization, and provide education and resources to help integrate virtual care into emerging value-based delivery models. Visit the ATA COVID-19 Resource Center. @americantelemed #gotelehealth #ATApolicy

SOURCE The American Telemedicine Association (ATA)


These press releases may also interest you

at 07:00
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

at 06:40
The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation . Shareholders who...

at 06:00
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...



News published on and distributed by: